Document Detail


Inhibition of Cyclin D1 by shRNA Is Associated with Enhanced Sensitivity to Conventional Therapies for Head and Neck Squamous Cell Carcinoma.
MedLine Citation:
PMID:  22213296     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Overexpression of cyclin D1 is associated with resistance to chemotherapy and radiotherapy in several types of cancer including head and neck squamous cell carcinoma (HNSCC).
MATERIALS AND METHODS: Cyclin D1 was silenced in an HNSCC cell line and its effect tested in sensitizing the cells to cisplatin, in vitro as well as in vivo. The HNSCC cell line NT8e, which is a chemoresistant, cyclin D1 over-expressing cell line, was used in the study. RNAi (shRNA) against cyclin D1 was designed and cloned in a vector.
RESULTS: Stable silencing of cyclin D1 resulted in delayed cell cycle progression and significantly sensitized the cells to cisplatin. Effective cell kill was achieved at a much lower therapeutic dose in vivo.
CONCLUSION: Suboptimal concentrations of cisplatin could be used in vivo to eradicate xenograft tumors indicating the promise of combining vector-based cyclin D1 silencing with chemotherapy to achieve maximum tumor regression.
Authors:
Vishal Kothari; Rita Mulherkar
Related Documents :
21600276 - Genotoxic and clastogenic activity of saponins extracted from nauclea bark as assessed ...
21671256 - Purkinje cell protein 4 positively regulates neurite outgrowth and neurotransmitter rel...
20859856 - Is it more reasonable to categorize frontal cells on the basis of their location rather...
15486016 - Differential involvement of oriens/pyramidale interneurones in hippocampal network osci...
19168646 - Changes in barotolerance, thermotolerance, and cellular morphology throughout the life ...
6330556 - Effects of caffeine, cyclic 3', 5' adenosine monophosphate and cyclic 3', 5' guanosine ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-01-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  121-8     Citation Subset:  IM    
Affiliation:
ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India. rmulherkar@actrec.gov.in.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma.
Next Document:  Naringin Inhibits Tumor Growth and Reduces Interleukin-6 and Tumor Necrosis Factor ? Levels in Rats ...